Italy's Clinical Research Landscape: Strengths, Weaknesses, and Strategic Implications

Italy's Clinical Research Landscape: Strengths, Weaknesses, and Strategic Implications

Italy holds a strong position in European clinical research volume, ranking fourth overall. However, significant delays in patient enrollment are hindering its competitiveness and attractiveness for global trials. For pharma BD and regulatory teams weighing country prioritization, the data demands a closer look.

Key Takeaways

• Italy ranks fourth in Europe for the total number of clinical trials activated, demonstrating a solid foundation in research infrastructure.
• A critical bottleneck exists in patient enrollment, with Italy averaging 148 days to initiate this phase — 36 days longer than Spain.
• These enrollment delays impact Italy's overall attractiveness for international clinical trials, potentially leading to lost opportunities and reduced investment.
• Addressing operational inefficiencies is crucial for Italy to climb the European clinical research rankings and maximize its potential.

What Happened: The Data Behind Italy's Enrollment Gap

The 2025 report Missed Opportunities, produced by the Laboratory on the Management of Clinical Trials at Altems — Alta Scuola di Economia e Management dei Sistemi sanitari of the Università Cattolica del Sacro Cuore in collaboration with Farmindustria, delivers the clearest picture yet of Italy's paradox. The country activates a high volume of clinical trials relative to its European peers, securing fourth place continent-wide. But the time required to move from activation to actual patient enrollment tells a starkly different story.

On average, Italian trial sites take 148 days to begin the enrollment phase. Spain, by comparison, completes the same step in roughly 112 days. That 36-day gap is not a rounding error — it represents a structural drag on trial feasibility that compounds across every study. The Altems-Farmindustria analysis estimated that every 2.5 days of delay carries measurable cost consequences, eroding the economic case for selecting Italy as a trial location when sponsors operate under fixed development timelines and budget constraints.

The findings align with broader European trends flagged by industry groups. EFPIA data showed 60,000 fewer clinical trial places for Europeans despite a global surge in research projects, attributing the decline to less favorable regulatory environments and funding structures across the continent. For Italy specifically, the problem is not a lack of scientific capacity — it is an operational one.

How Should Pharma BD Teams Respond to Italy's Enrollment Delays?

For business development professionals building country selection models, Italy's enrollment lag introduces a tangible variable into go/no-go decisions. A site that activates quickly but enrolls slowly inflates per-patient costs and extends timelines — two outcomes that directly conflict with portfolio planning goals.

The competitive implications are concrete. Spain, Germany, and France all offer faster enrollment pathways, and sponsors with global protocols increasingly allocate sites based on activation-to-first-patient-in metrics rather than reputational prestige alone. Italy's fourth-place ranking in trial volume means the academic infrastructure and investigator expertise exist, but the administrative friction around patient identification and site activation undermines the value proposition.

BD teams should consider a segmented approach. Italy may still warrant inclusion in therapeutic areas where its centers of excellence are irreplaceable — rare diseases, oncology subspecialties, or indications with highly concentrated patient populations. For large-phase enrollment-driven studies, however, the 148-day average should trigger a hard cost-benefit analysis against alternative geographies.

R&D budget planners should also model the downstream impact. A 36-day enrollment delay per site across a 40-site European trial represents nearly four months of cumulative lag — time that translates directly into delayed regulatory submissions, compressed market exclusivity windows, and deferred revenue recognition.

What Role Do Regulatory Bodies Play in Fixing This?

The European Medicines Agency has pursued regulatory harmonization across member states for years, most notably through the EU Clinical Trials Regulation (CTR) that took full effect in early 2022. The CTR's centralized Clinical Information System was designed to reduce administrative fragmentation, but national-level implementation varies. Italy's Agenzia Italiana del Farmaco (AIFA) retains significant authority over local trial authorization timelines, and the gap between EU-level frameworks and national execution remains a bottleneck.

The EMA's clinical trials guidance documents set the harmonized baseline, but Italy's site-level processes — ethics committee approvals, clinical trial agreement negotiations, and patient referral pathways — operate on timelines that the EU framework alone cannot compress.

The FDA's efforts on clinical trial harmonization through ICH guidelines add another layer. Companies running global programs that span US and EU sites face a dual regulatory calculus, and Italy's enrollment delays compound the complexity of maintaining synchronized timelines across jurisdictions. Sponsors filing in both markets may deprioritize Italy to avoid creating an asymmetric enrollment profile that complicates pooled analyses.

Can Italy Close the Enrollment Gap?

The pathways to improvement are identifiable, even if execution remains uneven. Streamlining ethics committee reviews — Italy has historically required approvals from multiple local committees rather than a single centralized body — would compress one of the longest pre-enrollment phases. The CTR's shared assessment model was intended to address this, but uptake has been slow.

Investing in digital patient identification tools and real-time data on eligible patient populations at individual sites would reduce the 148-day average. Countries that have adopted centralized recruitment platforms and electronic health record screening have cut enrollment initiation timelines by weeks. Italy's hospital networks are fragmented across regional systems, making interoperability a prerequisite — and a challenge.

Industry collaboration through Farmindustria and patient advocacy groups could also accelerate reform. Transparent benchmarking data — site-level enrollment performance published and accessible to sponsors — would create competitive pressure among Italian centers to improve, a dynamic that currently lacks a mechanism.

At the EU level, continued pressure from bodies like EFPIA and the EMA to enforce consistent CTR implementation across member states sets a floor. Italy benefits when the entire bloc raises its standards, but national authorities must translate that floor into local practice.

Frequently Asked Questions

Q: What is Italy's current standing in European clinical research?
A: Italy ranks fourth in Europe for the total number of clinical trials activated, according to the 2025 Altems-Farmindustria report Missed Opportunities. This reflects strong academic infrastructure and investigator capacity, but volume alone does not capture competitiveness.

Q: How long does patient enrollment take in Italy compared to other European countries?
A: Italy averages 148 days to begin the patient enrollment phase — 36 days longer than Spain's approximately 112-day average. This gap is the primary drag on Italy's attractiveness for time-sensitive global trials.

Q: What is the estimated cost of these enrollment delays?
A: The Altems-Farmindustria analysis estimated that every 2.5 days of delay carries measurable cost consequences for trial sponsors, spanning extended site monitoring, delayed milestone payments, and compressed commercial timelines.

Q: How do Italy's enrollment delays affect pharmaceutical company strategy?
A: Slow enrollment can lead sponsors to deprioritize Italy in favor of faster-enrolling countries, particularly for large Phase III programs where timeline predictability is critical. BD teams may still select Italy for niche therapeutic areas where its centers of excellence are unmatched, but the default calculus has shifted.

Q: What regulatory reforms could improve Italy's clinical trial competitiveness?
A: Faster ethics committee approvals, adoption of centralized patient recruitment platforms, and full implementation of the EU Clinical Trials Regulation's harmonized assessment framework are among the most impactful levers. National-level action by AIFA and regional health authorities is required to complement the EU-level infrastructure already in place.

What to Watch

Italy's next move matters. The country has the scientific depth to compete for top-three European clinical research status, but enrollment speed is the binding constraint. Sponsors should monitor AIFA's implementation of streamlined ethics review processes, track site-level performance data as it becomes available through industry benchmarking initiatives, and reassess country allocation models as the EU CTR matures. The gap between Italy's potential and its current performance is not a science problem — it is an execution problem, and it is solvable.

Sources: Il Sole 24 ORE; Altems-Farmindustria 2025 Report Missed Opportunities; EFPIA; ClinicalTrials.gov

Related coverage

• The Data Harmonization Imperative: How AI Is Solving Clinical Research's Biggest Bottleneck
• Myasthenia Gravis Clinical Trial Pipeline Expands as 25+ Companies Race to Redefine Myasthenia Gravis Treatment Landscape | DelveInsight — regulatory updates
• Nika Pharmaceuticals Inc OTCQB NIKA June 2026 Update: Key Developments and Strategic Implications